GE HealthCare Announces US Launch Of Longer Half-Life PET MPI Agent For Ischemia Detection

Flyrcado’s Long Half-Life And Stress-Test Compatibility Could Reshape Cardiac PET As GE HealthCare Targets 2026 For Its Photon-Counting CT Launch.

GE HealthCare is pursuing a dual-front imaging strategy with its PET MIP agent Flyrcado for detecting artery disease: It lasts longer than current PET scan tracers and allows patients to do treadmill-based stress tests alongside the scan.

Flyrcado’s CMS pass-through status, which lasts up to three years, ensures temporary reimbursement above the standard outpatient payment rate.
Key Takeaways
  • Flyrcado, GEHC’s new cardiac PET imaging agent, has CMS pass-through status, which lasts up to three years, ensures temporary reimbursement above the standard outpatient payment rate and is expected to generate $30m in 2025 and up to $500m by 2028.

GE HealthCare’s CEO has high expectations for Flyrcado, a positron emission tomography myocardial perfusion imaging (PET MPI) agent for detecting...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Diagnostic Imaging

More from Medtech Insight

Execs On The Move: July 14–18, 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

Time For Medtech To Have Its Say On Critical Changes In EU Framework Legislation

 

In revising the foundations of EU product legislation, the European Commission aims to increase harmonization, cut regulatory burdens and promote digital tools to boost compliance and safety.

Medtech M&A Resurges: How To Define Startup Exit Strategy

 

The medtech M&A landscape is experiencing a resurgence fueled by significant capital from private equity and venture firms, says Alex Wakefield, CRO of AcuityMD. Building strong relationships with physicians remains crucial in medtech, and defining an exit strategy early is imperative.